Notice of Extraordinary General Meeting 9 September 2016
(Oslo, Norway, 19 August 2016) An Extraordinary General Meeting of Bionor Pharma ASA will be held on Friday 9 September 2016 at 12:00 hours at Kronprinsesse Märthas Plass 1, Oslo, Norway in the 9th floor meeting room.
The notice of the Extraordinary General Meeting is attached hereto and includes detailed registration and proxy instructions.
For online registration of attendance and advance voting please click here.
All relevant documents and link to online registration of attendance and advance voting can be found on the company's website.
Please note that to attend the Extraordinary General Meeting, attendants must be registered shareholders five working days prior to the meeting – 2 September 2016.
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Cecilie Grue, Director Legal Affairs, +47 99162486, email@example.com
Bionor Pharma's mission is to enable the immune system to fight HIV infection. Bionor is the first company, which has successfully completed a clinical trial using the shock and kill approach, thereby creating a strong foundation for further advancing its therapeutic vaccine Vacc-4x in combination with other agents towards a functional cure. The company believes it has first mover potential based on clinical results to date and early adoption of the shock and kill strategy. In December 2015, Bionor announced that the HIV trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by reducing latent HIV reservoir and further demonstrated control of viral load. Bionor currently retains full ownership rights to the HIV immunotherapy Vacc-4x, i.e., the upside potential from partnering or licensing remains with the company's shareholders. Bionor is listed on Oslo Børs (OSE:BIONOR). More information about Bionor is available at www.bionorpharma.com.
Link to all materials, online registration and voting form.